ArticleCancers2020
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- Integrated Evolutionary and Multi-Omic Analysis of STAT Family Activation Across Solid Tumors.Genes · 2026Article
- Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study.Blood advances · 2026Article
- T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype.Frontiers in immunology · 2026Article
- STAT3 SH2 Domain Aspartic Acid 661 Mutations Activate Immune Gene Programs.Journal of cellular and molecular medicine · 2026Article
- Transcriptomic landscape of CD8+ and CD4 + T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations.Leukemia · 2025Article
- Anti-thymocyte globulin in immune-mediated cytopenias: A monocentric experience and literature review.British journal of haematology · 2025Article
- NK-type large granular lymphocyte leukemia comes of age.HemaSphere · 2025Review
- Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia.Haematologica · 2025Article
- T-cell clones of uncertain significance. When is the rogue clone dangerous?Haematologica · 2025Review
- Golidocitinib was used for the first time to treat refractory NK-Large Granular lymphocytic leukemia with a STAT3 mutation, accompanied by hemolytic anemia: a case report.Frontiers in immunology · 2025Article
- Altered immune cell profiles in blood of mature/peripheral T-cell leukemia/lymphoma patients: an EuroFlow study.Frontiers in immunology · 2025Article
- Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia.Annals of hematology · 2025Article
- HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients.Discover oncology · 2024Article
- Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations.Hematology. American Society of Hematology. Education Program · 2024Review
- The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders.Blood cancer journal · 2024Review
- A novel NKp80-based strategy for universal identification of normal, reactive and tumor/clonal natural killer-cells in blood.Frontiers in immunology · 2024Article
- A case of T-cell large granular lymphocytic leukemia with autoimmune hemolytic anemia and literature review.American journal of translational research · 2024Article
- JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences.Journal of clinical immunology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Noemí Muñoz-GarcíaTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-8381-301X
María Jara-AcevedoTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Carolina CaldasTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Paloma BárcenaTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Antonio LópezTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Noemí PuigBiomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-7535-3861
Miguel AlcocebaBiomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Paula FernándezInstitut für Labormedizin, Kantonsspital, 5001 Aarau, Switzerland.
Neus VillamorBiomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Juan A Flores-MonteroTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-1119-4387
Karoll GómezHematology Service, Juan Ramón Jiménez Hospital, 21005 Huelva, Spain.
María Angelina LemesHematology Service, Dr. Negrín Hospital, 35010 Las Palmas de Gran Canaria, Spain.
Jose Carlos HernándezHematology Service, Punta de Europa Hospital, Algeciras, 11207 Cadiz, Spain.
Iván Álvarez-TwoseBiomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Jose Luis GuerraHematology Service, Virgen de la Luz Hospital, 16002 Cuenca, Spain.
Marcos GonzálezBiomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Alberto OrfaoTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-0007-7230
Julia AlmeidaTranslational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0003-3124-8917
Universidad de Salamanca · ESInstituto de Salud Carlos III · ESHospital Juan Ramón Jiménez · ESHospital Universitario de Gran Canaria Doctor Negrín · ESHospital Virgen de la Luz · ESZentrum für Labormedizin · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
large granular lymphocytic leukemianeutropenianormal leukocyte subsetsSTAT3 and STAT5B mutationsT and NK cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.